195 related articles for article (PubMed ID: 35620187)
21. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
22. Liver graft rejection following immune checkpoint inhibitors treatment: a review.
Hu B; Yang XB; Sang XT
Med Oncol; 2019 Oct; 36(11):94. PubMed ID: 31605245
[TBL] [Abstract][Full Text] [Related]
23. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.
Gao Q; Anwar IJ; Abraham N; Barbas AS
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944927
[TBL] [Abstract][Full Text] [Related]
24. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
Front Immunol; 2021; 12():794099. PubMed ID: 34950153
[TBL] [Abstract][Full Text] [Related]
25. Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Lu LC; Hsu C; Shao YY; Chao Y; Yen CJ; Shih IL; Hung YP; Chang CJ; Shen YC; Guo JC; Liu TH; Hsu CH; Cheng AL
Liver Cancer; 2019 Nov; 8(6):480-490. PubMed ID: 31799205
[TBL] [Abstract][Full Text] [Related]
26. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
28. Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art.
Laschtowitz A; Roderburg C; Tacke F; Mohr R
J Hepatocell Carcinoma; 2023; 10():181-191. PubMed ID: 36789252
[TBL] [Abstract][Full Text] [Related]
29. Clinical Significance of De Novo Malignancy After Liver Transplant: A Single-Center Study.
Kim S; Rovgaliyev B; Lee JM; Lee KW; Hong SK; Cho JH; Yoon KC; Yi NJ; Suh KS
Transplant Proc; 2021; 53(1):200-206. PubMed ID: 32409224
[TBL] [Abstract][Full Text] [Related]
30. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
Ito S; Asahina H; Honjo O; Tanaka H; Honda R; Oizumi S; Nakamura K; Takamura K; Hommura F; Kawai Y; Ito K; Sukoh N; Yokoo K; Morita R; Harada T; Takashina T; Goda T; Dosaka-Akita H; Isobe H;
Lung Cancer; 2021 Jun; 156():12-19. PubMed ID: 33872943
[TBL] [Abstract][Full Text] [Related]
32. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma.
Lewin SM; Mehta N; Kelley RK; Roberts JP; Yao FY; Brandman D
Liver Transpl; 2017 Aug; 23(8):1015-1022. PubMed ID: 28340509
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.
Wassmer CH; El Hajji S; Papazarkadas X; Compagnon P; Tabrizian P; Lacotte S; Toso C
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760542
[TBL] [Abstract][Full Text] [Related]
34. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
[TBL] [Abstract][Full Text] [Related]
35. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?
Adam R; Azoulay D; Castaing D; Eshkenazy R; Pascal G; Hashizume K; Samuel D; Bismuth H
Ann Surg; 2003 Oct; 238(4):508-18; discussion 518-9. PubMed ID: 14530722
[TBL] [Abstract][Full Text] [Related]
36. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.
Murakami N; Mulvaney P; Danesh M; Abudayyeh A; Diab A; Abdel-Wahab N; Abdelrahim M; Khairallah P; Shirazian S; Kukla A; Owoyemi IO; Alhamad T; Husami S; Menon M; Santeusanio A; Blosser CD; Zuniga SC; Soler MJ; Moreso F; Mithani Z; Ortiz-Melo D; Jaimes EA; Gutgarts V; Lum E; Danovitch GM; Cardarelli F; Drews RE; Bassil C; Swank JL; Westphal S; Mannon RB; Shirai K; Kitchlu A; Ong S; Machado SM; Mothi SS; Ott PA; Rahma O; Hodi FS; Sise ME; Gupta S; Leaf DE; Devoe CE; Wanchoo R; Nair VV; Schmults CD; Hanna GJ; Sprangers B; Riella LV; Jhaveri KD;
Kidney Int; 2021 Jul; 100(1):196-205. PubMed ID: 33359528
[TBL] [Abstract][Full Text] [Related]
37. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival.
Chagas AL; Felga GEG; Diniz MA; Silva RF; Mattos AA; Silva RCMA; Boin IFSF; Garcia JHP; Lima AS; Coelho JCU; Bittencourt PL; Alves VAF; D'Albuquerque LAC; Carrilho FJ;
Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1148-1156. PubMed ID: 31247632
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
Yan J; Tan C; Gu F; Jiang J; Xu M; Huang X; Dai Z; Wang Z; Fan J; Zhou J
Liver Transpl; 2013 May; 19(5):507-20. PubMed ID: 23408515
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
